Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

Chronic myelogenous leukemia (CML) is caused by the constitutively active tyrosine kinase Bcr-Abl and treated with the tyrosine kinase inhibitor (TKI) imatinib. However, emerging TKI resistance prevents complete cure. Therefore, alternative strategies targeting regulatory modules of Bcr-Abl in addit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Grebien, Florian, Hantschel, Oliver, Wojcik, John, Kaupe, Ines, Kovacic, Boris, Wyrzucki, Arkadiusz M., Gish, Gerald D., Cerny-Reiterer, Sabine, Koide, Akiko, Beug, Hartmut, Pawson, Tony, Valent, Peter, Koide, Shohei, Superti-Furga, Giulio
Format:	Artigo
Language:	Inglês
Published:	Cell Press 2011
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3202669/ https://ncbi.nlm.nih.gov/pubmed/22000011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cell.2011.08.046
Tags:	Add Tag No Tags, Be the first to tag this record!

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

Similar Items